1. Gossamer Bio presents seralutinib at ERS Congress 2025. 2. Five presentations focus on seralutinib's effects on pulmonary diseases. 3. Collaboration with Chiesi Group enhances seralutinib's development. 4. Results may attract investor interest in GOSS stock. 5. Event scheduled from September 27 to October 1, 2025.
Positive presentation details about seralutinib could boost market confidence, similar to prior successful drug disclosures.
The strong emphasis on innovative presentations surrounding seralutinib's applications signals growth potential for GOSS.
Increased visibility and investor interest leading to potential price movements are imminent around the event date.
- One Oral and Four Poster Presentations Highlight Seralutinib's Potential Across Pulmonary Hypertension and Fibrotic Lung Disease -
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralutinib will be presented at the European Respiratory Society (ERS) Congress 2025, which takes place from September 27th through October 1st in Amsterdam, Netherlands and online. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.
ERS 2025 Presentation Details:
Session Type: Oral Presentation
Session Title: From omics to targets: emerging insights into chronic pulmonary disease mechanisms (Session 94)
Session Date & Time: September 28th, 9:30am – 10:45am CEST
Location: Amtrium
Abstract Number: OA1201
Presentation Title: Seralutinib targets fibrotic pathways in IPF: Evidence from single‑cell transcriptomics
Presenter: Dr. Rui Benfeitas (Chiesi Group)
Session Type: Poster Presentation
Session Title: Preclinical insights into rare diseases (Session 75)
Session Date & Time: September 28th, 8:00am – 9:30am CEST
Location: PS-7
Abstract Number: PA1039
Presentation Title: Seralutinib demonstrates in vitro reduction of vascular inflammatory drivers underlying pulmonary hypertension
Presenter: Dr. Zhaoqing Ding (Gossamer Bio)
Session Type: Poster Presentation
Session Title: Translational studies in interstitial lung disease of known causes (Session 149)
Session Date & Time: September 28th, 12:30pm – 2:00pm CEST
Location: PS-34
Abstract Number: PA1864
Presentation Title: Seralutinib shows significant anti-fibrotic effects: Evidence from patient-derived models
Presenter: Dr. Ravikumar Sitapara (Gossamer Bio)
Session Type: Poster Presentation
Session Title: Pulmonary arterial hypertension: risk assessment and impact of current and newly developed treatments (Session 423)
Session Date & Time: September 30th, 8:00am – 9:30am CEST
Location: PS-38
Abstract Number: PA5143
Presentation Title: Seralutinib increases small pulmonary artery vessel volume and reduces vessel wall remodeling: Insights from AI-driven CT imaging analysis
Presenter: Dr. Raúl San José Estépar (Brigham Women's Hospital)
Session Type: Poster Presentation
Session Title: Pulmonary arterial hypertension: risk assessment and impact of current and newly developed treatments (Session 423)
Session Date & Time: September 30th, 8:00am – 9:30am CEST
Location: PS-38
Abstract Number: PA5144
Presentation Title: Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an in vitro model of pulmonary fibrosis
Presenter: Dr. Zhaoqing Ding (Gossamer Bio)
About Gossamer Bio
Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250922224756/en/
For Investors and Media
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com